NCT02681224已完成不适用
TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest
Goldman, Butterwick, Fitzpatrick and Groff1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2015年9月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- Rate of Healing
研究概览
简要总结
A single site, double-blind, randomized, placebo-controlled, clinical study comparing the difference between a novel healing gel and a placebo gel on post laser-resurfacing chests.
详细描述
This is a double-blind, randomized, placebo-controlled, chest clinical study with a single study site. Forty subjects will receive fractionated CO2 laser resurfacing of the chest. . Immediately following the procedure (Day 0), postoperative gel randomized to the chest (TR-987 or placebo), will be applied with a thickness of 1-2 mm by a non-blinded coordinator, along with a split-chest Silon TSR bandage. Subjects will return for follow up on Day 1, with the gel and split chest Silon TSR© bandages applied by non-blinded coordinator during visit, with further follow-up on Days 6, 8, 10, 13 and 28. Both subjects and evaluating investigator will be blinded to randomization schedule (performed by an unblinded coordinator). Subject will apply gels and split chest Silon TSR© bandages at home on Days 2, 3 and 4 when not visiting clinic.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Females or males in good general health greater than 18 years of age.
- •Must be willing to give and sign a HIPPA form, informed consent form, and a photographic release form
- •Subject is planning to undergo fractionated CO2 laser resurfacing to the chest
- •A potential subject's must exhibit:
- •-Skin phototype of Fitzpatrick Type I-IV
- •For FEMALE SUBJECT OF CHILDBEARING POTENTIAL, must have had a regular menstrual cycle prior to study entry (a female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation) and is willing to use an acceptable form of birth control during the entire course of the study [i.e., acceptable methods of birth control are oral contraceptives, contraceptive patches/rings/implants Norplant®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of partner with a documented second acceptable method of birth control should the subject become sexually active]. All systemic birth control measures must be in consistent use at least 30 days prior to study participation. Postmenopausal is defined as having the last menstrual cycle in at least 12 months
- •Negative urine pregnancy test results at the time of study entry (if applicable)
- •Must be willing to comply with study dosing and complete the entire course of the study.
排除标准
- •A subject with any UNCONTROLLED systemic disease at the discretion of the Investigator. A potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study
- •A subject with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
- •A subject with recently excessive exposure to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing) or expectations of tanning during the time of the study or has used self-tanner within 7 days of study entry.
- •A subject with history of or the presence of any skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis) at the discretion of the investigator.
- •A subject with an active bacterial, fungal, or viral infection in the treatment area.
- •A subject with known allergies or sensitivities to benzocaine, lidocaine, tetracaine, PABA (para-aminobenzoic acid), or other local anesthetics of the amide or ester family sedation medication.
- •A subject with known allergy or sensitivity to propylene glycol or any other ingredient of topical TR-987 or placebo.
- •A subject receiving any topical products containing alpha-hydroxy acids, salicylic acid, and vitamins C or E (includes derivatives thereof) on the chest within 14 days prior to or during the study period, other than the study products
- •A subject receiving any investigational drug and/or has had a microdermabrasion (light or medium skin peel) treatment on their chest within 30 days prior to or during the study period
- •A subject using any topical tretinoin product or derivative on their chest within 12 weeks prior to or during the study period
- •A subject receiving a chemical peel, any systemic steroids, a non-ablative laser, light or radio frequency treatment and/or has had a Dermabrasion (deep skin peel) or ablative laser treatments on their chest must have discontinued the drug/treatment and/or have completed the treatment or the procedure at least 3 months prior to entering the study.
- •A subject with a history of keloids or hypertrophic scars
- •A subject that has previously been treated with a systemic retinoid within the past year (e.g., Accutane®, Roche Dermatologics)
- •A female subject who is pregnant, nursing an infant or planning a pregnancy during the study [throughout the course of the study, women of child-bearing potential must use reliable forms of contraception (i.e., oral contraceptive, contraceptive patches/rings/implants Norplant®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence, or vasectomies of partner with a documented second acceptable method of birth control should the subject become sexually active].
- •Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.
研究组 & 干预措施
Active Product with Occlusion
Active Comparator
TR987 Gel with Silon Bandage
干预措施: TR987 Gel with Silon Bandage (Other)
Active Product without Occlusion
Active Comparator
TR987 without Silon Bandage
干预措施: TR987 without Silon Bandage (Other)
Placebo Gel with Occlusion
Placebo Comparator
Placebo Gel with Silon Bandage
干预措施: Placebo Gel with Silon Bandage (Other)
Placebo Gel without Occlusion
Placebo Comparator
Placebo Gel without Silon Bandage
干预措施: Placebo Gel without Silon Bandage (Other)
结局指标
主要结局
Rate of Healing
时间窗: Day 28
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne VulgarisAcne VulgarisNCT01628549Almirall, S.A.285
已完成
3 期
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in AdultsMigraine DisordersMigraine, AcuteNCT00573170GlaxoSmithKline375
已完成
2 期
Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917Diabetes Mellitus, Type 2NCT00290940Daiichi Sankyo400
已完成
3 期
A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid ArthritisRheumatoid ArthritisNCT00531817Hoffmann-La Roche619
已完成
3 期
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)DepressionMajor Depressive DisorderNCT01157078AstraZeneca319